Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
Related Questions
In patients with Met-ALD, how do you approach their treatment plan?
In a patient with low (or normal) BMI but findings of steatosis on imaging, no cardiometabolic comorbidities, and very elevated CAP scores, what are your next diagnostic and therapeutic steps to identify the cause of their steatosis and subsequent management?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
How would you manage a patient who presents with hair loss that began after they started a GLP-1 inhibitor?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
In patients with MASLD/MASH, do you perform any cardiac testing to create a patient's risk profile, given that cardiac complications are the top cause of morbidity and mortality in this patient population (especially those with advanced fibrosis)?
